Evidence map›Paper›PMID 27818752›Full record

ArticleClinical kidney journal2013

The clinical impact of plasma leptin levels in a cohort of chronic kidney disease patients.

Rodrigo Bueno de Oliveira, Sophie Liabeuf, Hirokazu Okazaki, Aurelie Lenglet, Lucie Desjardins, Horst-Dieter Lemke, Raymond Vanholder, Gabriel Choukroun, Ziad A Massy, European Uremic Toxin Work Group (EUTox)

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Rodrigo Bueno de OliveiraINSERM U-1088, The Jules Verne University of Picardy , Amiens , France.
Sophie LiabeufINSERM U-1088, The Jules Verne University of Picardy, Amiens, France; Clinical Research Center, Division of Clinical Pharmacology, Amiens University Medical Center, Amiens, France; The Jules Verne University of Picardy, Amiens, France.
Hirokazu OkazakiINSERM U-1088, The Jules Verne University of Picardy , Amiens , France.
Aurelie LengletINSERM U-1088, The Jules Verne University of Picardy, Amiens, France; Clinical Research Center, Division of Clinical Pharmacology, Amiens University Medical Center, Amiens, France; The Jules Verne University of Picardy, Amiens, France.
Lucie DesjardinsClinical Research Center, Division of Clinical Pharmacology, Amiens University Medical Center, Amiens, France; The Jules Verne University of Picardy, Amiens, France.
Horst-Dieter LemkeeXcorLab GmbH , Obernburg , Germany.
Raymond VanholderNephrology-Dialysis-Transplantation Department, Department of Internal Medicine , University Hospital , Ghent , Belgium.
Gabriel ChoukrounDivision of Nephrology , Amiens University Medical Center , Amiens , France.
Ziad A MassyINSERM U-1088, The Jules Verne University of Picardy, Amiens, France; Clinical Research Center, Division of Clinical Pharmacology, Amiens University Medical Center, Amiens, France; The Jules Verne University of Picardy, Amiens, France; Division of Nephrology, Ambroise Paré Hospital, Paris Ile de France Ouest (UVSQ) University, Paris-Boulogne Billancourt, France.
European Uremic Toxin Work Group (EUTox)
Inserm · FRCentre Hospitalier Universitaire Amiens-Picardie · FRUniversité de Picardie Jules Verne · FREXcorLab (Germany) · DEGhent University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent research has clarified the relationship between adipokines, metabolic syndrome (MS) and cardiovascular disease (CVD). The results of animal and clinical studies have revealed a positive relationship between leptin and vascular smooth muscle cell counts and calcification, arterial rigidity, carotid thickness and the incidence of CVD. However, despite leptin fulfilling the definition of a uremic toxin, its exact role in chronic kidney disease (CKD) has yet to be determined.

methodsOne hundred and forty-two CKD patients (stages 2-5D) participated in this study, and were followed for a minimum of 20 months at Amiens University Medical Center.

resultsLeptin was negatively correlated with the glomerular filtration rate (GFR), total adiponectin (TAdip) and high-molecular weight adiponectin and positively correlated with age, waist circumference, body mass index (BMI), aortic calcification score (ACS), C-reactive protein (CRP), triglycerides, insulin and parathormone (PTH). Leptin and insulin were significantly correlated with the MS score. The BMI, insulin, MS score and PTH were independent predictors of leptin levels (P = 0.002, 0.016, 0.028 and 0.017, respectively). Leptin, insulin and TAdip were independent predictors of the presence of MS (P = 0.05, 0.04 and 0.04). However, leptin levels were not significantly predictive of the clinical outcomes.

conclusionsOur study was the first to demonstrate a significant, independent link between leptin and MS (but not clinical outcomes) and PTH in patients at different CKD stages. Future studies will have to assess the involvement of leptin in MS and clinical outcomes in CKD, and the potential modulation of leptin by PTH.

Indexed as

adiponectinchronic kidney diseaseleptinmetabolic syndromeparathormone

Identifiers

PMID27818752
PMCPMC5094389
OpenAlexW2148481108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.